The Cell-Penetrating Peptide GV1001 Enhances Bone Formation Via Pin1-Mediated Augmentation of Runx2 and Osterix Stability

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2024 Jul 27

PMID 39062525

Authors

Meiyu Piao

Sung Ho Lee

Jin Wook Hwang

Hyung Sik Kim

Youn Ho Han

Kwang Youl Lee

Affiliations

Soon will be listed here.

Abstract

Peptide-based drug development is a promising direction due to its excellent biological activity, minimal immunogenicity, high in vivo stability, and efficient tissue penetrability. GV1001, an amphiphilic peptide, has proven effective as an anti-cancer vaccine, but its effect on osteoblast differentiation is unknown. To identify proteins interacting with GV1001, biotin-conjugated GV1001 was constructed and confirmed by mass spectrometry. Proteomic analyses were performed to determine GV1001's interaction with osteogenic proteins. GV1001 was highly associated with peptidyl-prolyl isomerase A and co-immunoprecipitation assays revealed that GV1001 bound to peptidyl-prolyl cis-trans isomerase 1 (Pin1). GV1001 significantly increased alkaline phosphatase (ALP) activity, bone nodule formation, and the expression of osteogenic gene markers. GV1001-induced osteogenic activity was enhanced by overexpression and abolished by knockdown. GV1001 increased the protein stability and transcriptional activity of Runx2 and Osterix. Importantly, GV1001 administration enhanced bone mass density in the OVX mouse model, as verified by µCT analysis. GV1001 demonstrated protective effects against bone loss in OVX mice by upregulating osteogenic differentiation via the Pin1-mediated protein stabilization of Runx2 and Osterix. GV1001 could be a potential candidate with anabolic effects for the prevention and treatment of osteoporosis.

References

Banno Y, Sasaki S, Kamata M, Kunitomo J, Miyamoto Y, Abe H . Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes. Bioorg Med Chem. 2017; 25(21):5995-6006. DOI: 10.1016/j.bmc.2017.09.031. View

Piga I, Magni F, Smith A . The journey towards clinical adoption of MALDI-MS-based imaging proteomics: from current challenges to future expectations. FEBS Lett. 2023; 598(6):621-634. DOI: 10.1002/1873-3468.14795. View

Lewiecki E, Miller P, Harris S, Bauer D, Davison K, Dian L . Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. J Clin Densitom. 2013; 17(4):490-5. DOI: 10.1016/j.jocd.2013.09.018. View

Park J, Kim Y, Kim H, Jeon J, Kim T, Park J . The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma. Oncotarget. 2016; 7(46):75081-75093. PMC: 5342724. DOI: 10.18632/oncotarget.12057. View

Lee A, Harris J, Khanna K, Hong J . A Comprehensive Review on Current Advances in Peptide Drug Development and Design. Int J Mol Sci. 2019; 20(10). PMC: 6566176. DOI: 10.3390/ijms20102383. View

Lee S, Jeong H, Han Y, Cheong H, Kang B, Lee K . Prolyl isomerase Pin1 regulates the osteogenic activity of Osterix. Mol Cell Endocrinol. 2014; 400:32-40. DOI: 10.1016/j.mce.2014.11.017. View

Mander K, Harford-Wright E, Lewis K, Vink R . Advancing drug therapy for brain tumours: a current review of the pro-inflammatory peptide Substance P and its antagonists as anti-cancer agents. Recent Pat CNS Drug Discov. 2014; 9(2):110-21. DOI: 10.2174/1574889809666141111142740. View

Kim K, Yang H, Chang S, Kim Y, Lee K, Lee B . Potential repositioning of GV1001 as a therapeutic agent for testosterone‑induced benign prostatic hyperplasia. Int J Mol Med. 2018; 42(4):2260-2268. DOI: 10.3892/ijmm.2018.3759. View

Feigerlova E, Demarquet L, Gueant J . One carbon metabolism and bone homeostasis and remodeling: A review of experimental research and population studies. Biochimie. 2016; 126:115-23. DOI: 10.1016/j.biochi.2016.04.009. View

10.

Choonara B, Choonara Y, Kumar P, Bijukumar D, du Toit L, Pillay V . A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv. 2014; 32(7):1269-1282. DOI: 10.1016/j.biotechadv.2014.07.006. View

11.

Fanis P, Neocleous V, Papapetrou I, Phylactou L, Skordis N . Gonadotropin-Releasing Hormone Receptor (GnRHR) and Hypogonadotropic Hypogonadism. Int J Mol Sci. 2023; 24(21). PMC: 10650312. DOI: 10.3390/ijms242115965. View

12.

Marie P, Kassem M . Osteoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endocrinol. 2011; 165(1):1-10. DOI: 10.1530/EJE-11-0132. View

13.

Gupta T, Das N, Imran S . The Prevention and Therapy of Osteoporosis: A Review on Emerging Trends from Hormonal Therapy to Synthetic Drugs to Plant-Based Bioactives. J Diet Suppl. 2018; 16(6):699-713. DOI: 10.1080/19390211.2018.1472715. View

14.

Kyte J . Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs. 2009; 18(5):687-94. DOI: 10.1517/13543780902897631. View

15.

Liu J, Gray W, Davis M, Luo Y . Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interface Focus. 2013; 2(3):307-24. PMC: 3363024. DOI: 10.1098/rsfs.2012.0009. View

16.

Kim W, Islam R, Kim B, Cho Y, Yoon W, Baek J . Direct Delivery of Recombinant Pin1 Protein Rescued Osteoblast Differentiation of Pin1-Deficient Cells. J Cell Physiol. 2016; 232(10):2798-2805. DOI: 10.1002/jcp.25673. View

17.

Kim J, Yadav D, Kim S, Lee M, Park J, Kim B . Anti-cancer effect of GV1001 for prostate cancer: function as a ligand of GnRHR. Endocr Relat Cancer. 2018; 26(2):147-162. DOI: 10.1530/ERC-18-0454. View

18.

Komori T . [Cbfa1/Runx2, an essential transcription factor for the regulation of osteoblast differentiation]. Nihon Rinsho. 2002; 60 Suppl 3:91-7. View

19.

Gallacher S, Dixon T . Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010; 87(6):469-84. DOI: 10.1007/s00223-010-9420-x. View

20.

Matsubara T, Kida K, Yamaguchi A, Hata K, Ichida F, Meguro H . BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem. 2008; 283(43):29119-25. PMC: 2662012. DOI: 10.1074/jbc.M801774200. View